**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 48424

**Manuscript Type:** REVIEW

# Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance

Tuomisto AE *et al*. Systemic inflammation in colorectal cancer

Anne E Tuomisto, Markus J Mäkinen, Juha P Väyrynen

**Anne E Tuomisto, Markus J Mäkinen, Juha P Väyrynen,** Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90220, Finland

**Anne E Tuomisto, Markus J Mäkinen, Juha P Väyrynen,** Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, Oulu 90220, Finland

**Juha P Väyrynen**, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, United States

**ORCID number**: Anne Tuomisto (0000-0002-9949-1887); Markus J Mäkinen (0000-0002-9200-4118); Juha P Väyrynen (0000-0002-8683-2996).

**Author contributions:** All authors equally contributed to the literature review and design, writing, revision and editing of the manuscript.

**Conflict-of-interest statement**: The authors declare that there is no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author**: **Anne E Tuomisto, PhD, Research Scientist,** Department of Pathology, Oulu University Hospital and Medical Research Center Oulu, POB 21, Oulu 90029, Finland. anne.tuomisto@oulu.fi

**Telephone:** +358-29-4485946

**Fax:** +358-8-344084

**Received:** April 25, 2019

**Peer-review started:** April 25, 2019

**First decision:** May 24, 2019

**Revised:** June 7, 2019

**Accepted:** July 19, 2019

**Article in press:** July 19, 2019

**Published online:** August 21, 2019

Abstract

Systemic inflammation is a marker of poor prognosis preoperatively present in around 20%-40% of colorectal cancer patients. The hallmarks of systemic inflammation include an increased production of proinflammatory cytokines and acute phase proteins that enter the circulation. While the low-level systemic inflammation is often clinically silent, its consequences are many and may ultimately lead to chronic cancer-associated wasting, cachexia. In this review, we discuss the pathogenesis of cancer-related systemic inflammation, explore the role of systemic inflammation in promoting cancer growth, escaping antitumor defense, and shifting metabolic pathways, and how these changes are related to less favorable outcome.

**Key words**: Colorectal cancer; Inflammation; Prognosis; Cytokine; Chemokine; C-reactive protein; Glasgow prognostic score; Cachexia; Metastasis

**© The Author(s) 2019** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Increasing evidence indicates that systemic inflammation has wide-ranging effects on colorectal cancer (CRC) pathogenesis, spanning from supporting primary tumor growth by promoting tumor cell proliferation to helping angiogenesis by enhancing the availability of pro-angiogenic molecules, to suppressing anti-tumor immunity by recruiting anti-inflammatory cell types, and to shaping pre-metastatic niches to promote subsequent metastasis. Systemic inflammatory biomarkers, such as circulating acute phase proteins, cytokines, exosomes, and leukocytes, may help to classify CRC patients into useful prognostic categories. However, further larger-scale studies are needed to determine optimal marker combinations for selecting patients to receive specific treatments.

**Citation**: Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. World J Gastroenterol 2019; 25(31): 4383-4404 Available from:

**URL**: https://www.wjgnet.com/1007-9327/full/v25/i31/4383.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v25.i31.4383

**INTRODUCTION**

Interactions between tumor and host are important regulators of tumor progression[1–3]. These interactions are mediated by a complex network of cytokines, chemokines, growth factors, and matrix remodeling enzymes[4], reaching beyond the local tumor microenvironment and evoking systemic responses[1,5] that have an effect on the course of the disease[6]. Therefore, cancer progression is not only determined by factors intrinsic for the tumor, but is largely directed by multifaceted systemic processes[5].

Colorectal cancer (CRC) is the third most common cancer in the Western World, and the second most common cause of cancer deaths[7]. Systemic inflammation is most common in poorly differentiated and advanced CRC[8,9], but despite that it is also an independent indicator of less favorable outcome in CRC [10,11] and associated with shorter survival[6,12,13]. In the case of resectable disease, 21%–41% of CRC patients have increased serum levels of acute phase proteins such as CRP (C-reactive protein), indicating a systemic inflammatory response to the tumor[8,9,14].

Cancer-associated systemic inflammation is characterized by numerous alterations in many organ systems distant from the site or sites of inflammation. Activation of systemic inflammatory response in the liver results in a rapid increase in the production of acute phase proteins, such as CRP[15]. Many disabling symptoms of cancer patients, such as fever, anemia, fatigue and loss of appetite can be attributed to the presence of systemic inflammation, and finally, metabolic changes such as loss of muscle and negative nitrogen balance manifest in cachexia, a cancer-associated wasting syndrome[16].

Many markers of systemic inflammation are based on counts, ratios, or scores of circulating white cells or acute phase proteins, such as neutrophil/lymphocyte ratio (NLR) and Modified Glasgow Prognostic score (mGPS), a measure based on elevated serum CRP level and decreased serum albumin level[17], but more recent studies have also evaluated the significance of alterations in circulating cytokine, chemokine, and growth factor milieu[18–20], platelet transcriptome[21], or the composition of tumor-derived extracellular vesicles[22]. Released by tumor cells or non-neoplastic cells in tumor-elicited host reaction, IL6 (interleukin-6) is one of the most important mediators of systemic effects of inflammation, such as the production of acute phase proteins in the liver[15] and in cancer cachexia[16].

In this review, we aim to provide an overview of the factors contributing to systemic inflammatory responses in CRC, of their downstream processes in the responding tissues, as well as of the prognostic significance of systemic inflammatory markers in CRC.

**LITERATURE SEARCH**

A literature search using PubMed was conducted to identify articles relevant to the topic, using search terms: (“colorectal cancer” or “colon cancer” or “rectal cancer” or “colorectal neoplasia”) and (“systemic inflammation” or “CRP” or “Glasgow Prognostic Score” or “interleukin” or “chemokine” or “IL6” or “cytokine” or “CXCL\*” or “CCL\*” or “cachexia” or “inflammation” or “premetastatic niche”). The last search update was performed in March 2019. The titles and abstracts of the studies were screened for studies relevant to the review topic. Additional relevant publications were identified from the bibliographies of the included studies. Finally, this review was based on 195 publications identified during the search.

# FACTORS UNDERLYING SYSTEMIC INFLAMMATION IN CRC

The hallmarks of systemic inflammation in cancer patients include an increased production of proinflammatory cytokines and acute phase proteins that enter the circulation. Indeed, many proteins regulating the function of immune cells, or produced in large quantities by immune cells or in inflammatory conditions, have been reported to show altered serum levels in CRC patients compared to controls (Table 1). For example, when evaluating serum profiles of 13 cytokines, chemokines, and growth factors in 116 CRC patients and 86 healthy controls, it was found that serum levels of five of these proteins showed statistically significant alterations, including increased serum IL6, IL7, CXCL8 (IL8), and PDGFB levels, and decreased serum CCL2 levels[18]. Increased serum IL6 and CXCL8 levels in CRC have been reported in many studies, also summarized in two recent meta-analyses[23,24]. Further highlighting the presence of systemic inflammatory markers in the sera of CRC patients, in a systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of CRC[25], several of the most frequently reported diagnostic markers, such as CRP, VEGFA, and TIMP1, were related to the systemic inflammatory response.

The factors driving the systemic inflammatory response in CRC patients are complex and thereby not clear, but they are related to the interaction between neoplastic cells and the surrounding tumor microenvironment involving inflammatory cells, fibroblasts, extracellular matrix, and vasculature[5]. While tumor cells can variably express different cytokines and chemokines[26], immune cells and fibroblasts are capable of producing many of these factors at much higher levels[27–29].

## *Tumor cells produce inflammatory mediators*

Cancer cell express highly variable amounts of different cytokines, chemokines, and growth factors *in vitro*[26,30]. These include IL6, CCL2, CXCL8, CSF1 (macrophage colony-stimulating factor, M-CSF), and CSF2 (granulocyte-macrophage colony-stimulating factor, GM-CSF) (Table 2). These molecules contribute to a variety of functions related to systemic inflammation and cancer progression. For example, IL6, a seminal proinflammatory cytokine, regulates the acute phase response through the induction of acute phase proteins in hepatocytes and the differentiation of monocytes to macrophages[31], whereas CCL2 is essential for the recruitment of bone marrow derived monocytes into peripheral organs and tumors[32]. CXCL8 is an important proinflammatory chemokine, recruiting granulocytes but also promoting angiogenesis[33]. Both CSF1 and CSF2 stimulate the proliferation, differentiation, and survival of monocytes and macrophages, but while CSF1 is involved in M2-like anti-inflammatory macrophage polarization, CSF2 contributes to M1-like pro-inflammatory macrophage polarization[34].

Tumor-derived extracellular vesicles have recently gained more and more interest as potential regulators of tumor cell-immune cell interactions[35,36]. They are a heterogeneous group of lipid bilayer-delimited particles released by tumor cells in the tumor microenvironment and into the circulation[35,36]. They have been implicated in a variety of functions in tumor progression, such as contributing to angiogenesis, vascular leakiness, regulation of immune responses, and reprogramming of stromal recipient cells in subsequent metastatic areas[35,36]. Based on their size and contents, they can be divided into subcategories, such as microvesicles, exosomes, ectosomes, and oncosomes.

The contents of tumor-derived extracellular vesicles can be highly variable. For example, they have been reported to contain immunosuppressive proteins such as TGFB[37,38], protease enzymes such as MMP9[38], and growth factors such as IGF1[38]. Moreover, nucleic acids (micro RNAs, miRNAs; and long non-coding RNAs, lncRNAs) can be found in tumor-derived extracellular vesicles, and these can contribute to tumor cell and stromal cell proliferation and apoptosis, and the regulation of immune responses against the tumor[35,36]. For example, exosome-carried miR-21, miR-29a, and miR-222-3p have been associated with immunoregulatory functions in various tumor types[39]. However, current knowledge of miRNAs in the regulation of immune reactions is limited, and further investigation is required to show more clearly the significance of exosome-carried mRNAs in systemic inflammatory reactions, relative to other factors[35].

## *Tumor-infiltrating immune cells produce inflammatory mediators*

CRCs are infiltrated by a heterogeneous population of immune and inflammatory cells, including proinflammatory cells, such as CD8+ cytotoxic T cells, type 1 CD4+ helper T cells (Th1 cells), NK cells, and M1 macrophages, anti-inflammatory cells such as regulatory T cells (Treg), type 2 helper T cells (Th2 cells), M2 macrophages, and myeloid derived suppressor cells (MDSCs). Other cells include B lymphocytes, plasma cells, neutrophils, eosinophils and mast cells that co-operate with both immunoenhancing and immunosuppressing cells[40,41]. In contrast to systemic inflammatory response, which is associated with adverse outcome[12], an intense immune cell infiltrate, evaluated using hematoxylin and eosin stained sections[42–45] or by immunohistochemistry using antibodies to specific immune cell markers[46–50], has frequently been associated with improved survival in CRC, independent of tumor stage or other prognostic parameters. This has been attributed to the ability of immune cells to recognize transformed malignant cells and restrict tumor growth (immunosurveillance hypothesis)[3,51]. However, some types of immune cells such as Th17 cells, characterized by their production of IL17, a proinflammatory cytokine, have been associated with poor survival[52].

Immune cells are considered an important source of cytokines, chemokines, and growth factors in tumor microenvironment (Table 3), but a few recent studies have shown an inverse correlation or lack of correlation between local immune response and systemic inflammation. A recent study evaluated the relationships between serum levels of 13 cytokines and the densities of eight types of tumor-infiltrating immune cells (CD3+, CD8+, and FOXP3+ T cells, CD68+ macrophages, CD1a+ dendritic cells, CD83+ dendritic cells, ELANE+ neutrophils, and tryptase+ mast cells) in a cohort of 147 stage I–IV CRC patients. In that study, serum cytokines and tumor-infiltrating immune cells in CRC represented entities with high intra-group correlations but relatively weak positive inter-group correlations. High macrophage density was associated with increased serum CCL4 levels (which could reflect CCL4 production by macrophages or recruitment of CCR5+ macrophages in tumors as a response to CCL4) and high densities of CD3+ and CD8+ T cells were associated with increased serum IL12 levels (which indicates that systemic IL-12 levels may contribute to or reflect tumor-associated Th1 response). Yet another study reported a trend towards an inverse relationship between local inflammation and systemic inflammation in a cohort of stage II colon cancer patients[53].

The reasons underlying the relative weakness of the observed associations between tumor immune cell densities and serum levels of inflammatory markers are unclear. However, more precise definition of immune cell categories may be needed to show more closely defined associations with circulating inflammatory mediators. For example, general macrophage markers, such as CD68, do not adequately reflect the phenotypic diversity of macrophages, which can produce copious amounts of various cytokines depending on their polarization status (Figure 1)[28,54]. Also other immune cells, including T helper cells[55], B cells[56], neutrophils[57,58], produce different types and quantities of cytokines and chemokines related to the type of their activation. Based on this, for example, neutrophil categorization into proinflammatory N1 and anti-inflammatory N2 subsets has been suggested[59], but it is not as well established as T helper cell classification (Th1, Th2, Th17, Treg) or macrophage classification (M1 and M2)[60].

## *Cancer-associated fibroblasts produce inflammatory mediators*

Cancer-associated fibroblasts (CAFs) contribute to proliferative signaling, invasion and metastasis, angiogenesis, and inflammatory reactions[1,27]. Cancer cells and fibroblasts may form a reciprocal positive feedback loop where tumor cells release growth factors activating fibroblasts and, in return, fibroblasts secrete growth factors, such as IGF1, which stimulate the proliferation of cancer cells. Recently, such an IGF1-dependent feedback loop, promoting disease progression, was demonstrated in radiotherapy-activated CAFs in CRC mouse model and human CRC samples[61].

CAFs also produce several factors contributing to tumor inflammatory reactions (Table 4). For example, two recent studies indicated that stromal fibroblasts are an important source of IL6 in CRC[29,62]. Nagasaki *et al*[29] found that stromal fibroblasts had higher IL6 production than tumor cells, and that colon cancer cells enhanced IL6 production by isolated stromal fibroblasts. Moreover, in a xenograft mouse model, anti-IL6R antibody targeting stromal tissue showed greater anti-tumor activity than anti-IL6R antibody targeting xenografted cancer cells. Huynh *et al*[62] also demonstrated that CAFs are a major source of IL6 in human CRC samples, and found that IL6 production was associated with tumor promoting Th17 immune response. De Boeck *et al*[63] performed secretome profiling of CAFs isolated from human CRC samples, and found that in these experimental conditions, CAFs represent a rich source of cytokines, chemokines, proteases, and growth factors, such as CXCL8 involved in neutrophil recruitment, CCL5 involved in T cell recruitment, VEGFA involved in angiogenesis, and various matrix metalloproteinases (MMPs) (Table 4). MMPs play an important role in extracellular matrix remodeling during tumor invasion, but can also contribute to inflammatory regulation by, for example, cleaving chemokines and cytokines[64,65].

TGFB signaling is a central immunosuppressive pathway in CRC progression[66,67]. Recently, Hawinkels *et al*[68] demonstrated a positive feedback loop, where the interaction of tumor cells with resident fibroblasts results in hyperactivated TGFB signaling in both cell types. *In vitro*, the treatment of CAFs with TGFB increased their expression of collagen-1, PLAU (urokinase type plasminogen activator), various matrix MMPs, including MMP2, MMP3, and MMP9, tissue inhibitors of matrix metalloproteinases (TIMPs), and TGFB itself[68]. Collectively, these data support the role of CAFs in the regulation of cancer associate inflammatory reactions.

## *The role of tumor necrosis in systemic inflammation*

Necrosis, an uncontrolled process of cell death, provokes a rapid systemic inflammatory response that is necessary for the removal of dead tissues from the body by phagocytic cells like neutrophilic granulocytes and macrophages. Necrosis is also prevalent and represents an indicator of less favorable outcome in colorectal, renal, lung, and breast cancer[69–71]. Irreversible cell injury induces the systemic inflammatory response, when dying cells release proinflammatory molecules into the extracellular space, and this is further propagated when intracellular contents of the cells are exposed[72]. In trauma patients, mitochondrional damage-associated components released to the circulation are able to elicit systemic inflammation[73]. Väyrynen *et al*[74] and Guthrie *et al*[75] found that increasing amount of tumor necrosis in CRC is associated with higher levels of markers of systemic inflammation, such as modified Glasgow Prognostic Score (mGPS) and serum IL6, supporting the role of tumor necrosis in the induction of systemic inflammatory response. In addition, further supporting the association between hypoxia and systemic inflammation, Bousquet *et al*[76] showed that hypoxic conditions are related to a reduction of reactive oxygen species (ROS) production and increased damaged mitochondrial DNA (mtDNA) generation *in vitro* and that in rectal cancer patients with locally advanced disease, a low circulating ROS to damaged mtDNA ratio was associated with systemic inflammation. However, to our knowledge, the activation of systemic inflammation by tumor necrosis has not been demonstrated in more experimental studies.

# EFFECTS OF SYSTEMIC INFLAMMATION IN CRC

The effects of systemic inflammation span throughout the body; from primary tumors to metastases, liver, bone marrow, gut, skeletal muscle, and other organs (Figure 2). Recent studies have shown that even before metastatic disease, the systemic inflammatory response promotes tumor progression by modifying the interactions between neoplastic and non-neoplastic cells. The concept of pre-metastatic niche describes the process in which instead of being passive receivers of circulating tumor cells, the tissues and organs of a future metastasis are actively modified before the metastatic spread[77].

## *Liver*

The liver participates in a large number of tasks, such as macronutrient metabolism, blood volume regulation, detoxification of chemicals and several metabolites, and regulation of immune responses[78]. The liver synthesizes the majority of serum proteins, such as albumin, fibrinogen, clotting factors, transport proteins, complement proteins, and lipoproteins. It maintains whole body homeostasis via metabolism of carbohydrates, lipids, amino acids and vitamins, and it also functions as an immune organ that mediates and regulates systemic and local innate and adaptive immunity. Digestion and nutrient absorption in the gastrointestinal tract provide a constant source of antigens (and a potential route for pathogens) that enter the body, and liver sinusoids are thereby rich in antigen-presenting cells, NK cells and NKT-cells that have a key role both in immunotolerance and in the immune defense against pathogens. Liver mediates immunotolerance *via* complex interaction of hepatocytes, liver nonparenchymal cells and immune cells[79].

One of the best-known mechanisms of the liver in immunoregulation is the production of acute-phase proteins in response to inflammation[15]. An acute-phase protein has been defined as one whose plasma concentration increases (positive acute-phase proteins) or decreases (negative acute-phase proteins) during inflammation. Examples of positive acute-phase proteins include ceruloplasmin, CRP, haptoglobin, hepcidin, and SAA, whereas negative acute-phase proteins include albumin, transferrin, transthyretin, and alpha-fetoprotein[15]. IL6 has been established as one of the most important contributors to altered protein production in the liver during the acute phase response. During response to infection, circulating IL6 levels quickly increase, propagating inflammatory signaling throughout the body[80]. Notably, IL6 is one of the cytokines showing the greatest increase in CRC patients relative to healthy controls, and a further increase in metastatic disease compared to non-metastatic disease[18].

IL6 also appears to be one of the main contributors to altered hepatic metabolism during systemic inflammation. In a recent study, Flint *et al*[81] showed that, in a mouse CRC model, tumor-induced IL6 caused systemic metabolic changes, such as suppression of hepatic ketogenesis, which triggered marked glucocorticoid secretion from the liver. In turn, this suppressed intratumoral immunity and caused failure of anti-cancer immunotherapy. The IL6-ketogenesis suppression-glucocorticoid pathway in the liver may represent one of the mechanisms by which immunosuppression in tumor tissue, often observed in CRC patients with advanced cancer[40], is coupled with changes in liver function and systemic metabolic changes.

## *Bone marrow*

The immune system is governed by an appropriate balance of the lymphoid and myeloid responses. Hematopoietic stem cells (HSCs) reside in the bone marrow, producing different blood cell lineages in an highly organized manner[82]. HSCs respond rapidly to acute blood cell demand, such as injury or inflammation[83]. In patients with solid cancers, hematopoiesis is abnormal, leading to altered composition of hematopoietic progenitor cells, with myeloid-biased differentiation[84]. Accordingly, the systemic inflammation in cancer patients is widely reflected in hematological parameters, such as neutrophil-to-lymphocyte ratio, with neutrophil predominance over lymphocytes[85]. Together with CSF2, and CSF3, IL6 is among the leading myelopoiesis-driving cytokines[86].

A prolonged demand for myeloid cells – as in the case of a severe prolonged infection – results in sustained myelopoiesis that is characterized by the emergence of immature myeloid cells in the circulation and in peripheral tissues[87]. Many of these cells have been reported to harbor immunosuppressive functions, and this group of myeloid progenitor cells with immunosuppressive activity has been named as myeloid derived suppressor cells (MDSCs)[87,88]. In the peripheral blood, human polymorphonuclear MDSCs are CD11b+CD14-CD15+ and monocytic MDSCs are CD11b+CD14+CD15-HLADR-/low[87]. In addition to these gating criteria, functional suppression assays are required to precisely define MDSCs because of the overlap between their phenotype with that of more mature monocytes and granulocytes[87]. Besides peripheral blood, the presence of cells with MDSC-like phenotype has been reported in human CRC tissue[89].

The mechanisms by which MDSCs mediate immunosuppression and support tumor progression are complex and not fully understood[90]. However, several potential key pathways include the ARG1 pathway, IDO1-pathway, PD1/PDL1-pathway, and cytokine pathways (such as IL10 and IL6)[90,91] (Figure 3). L-arginine is an amino acid that is consumed by T cells and many other immune cells. MDSCs are characterized by high production of ARG1, which metabolizes L-arginine to L-ornithine and urea, resulting in L-arginine depletion and thus local immune suppression[92]. IDO1, expressed in a subset of MDSCs[87], converts tryptophan to kynurenine. The depletion of tryptophan suppresses activity in the mTORC1 signaling pathway, leading to autophagy in T cells and immunosuppression[93]. PD1 and PDL1 form an inhibitory immune checkpoint mechanism restricting excessive T cell activation[94]. The binding of PDL1, expressed on a subset of MDSCs[95], to PD1 causes T cell inhibition[96].

Besides myeloid immune cells, such as granulocytes, monocytes, and MDSCs, common myeloid progenitor cells can differentiate into megakaryocytes and red blood cells. However, instead of erythrocytosis (an increase in the number of red blood cells in the blood), CRC patients frequently have anemia (a decrease in the number of red blood cells or hemoglobin concentration), with a prevalence of 33%–43% in resectable disease[97–99]. Colorectal tumors frequently bleed into the lumen[100], explaining the iron deficiency associated with microcytic anemia in a subset of patients. However, systemic inflammation also appears to be one of the main determinants of low blood hemoglobin levels, and, in particular, normocytic anemia, in CRC patients[97–99]. There are several collaborating mechanisms linking systemic inflammation and anemia. First, hepcidin, an acute phase protein produced in the liver, limits iron absorption from small intestine[101,102] and iron availability for erythroid cells[102]. Second, pro-inflammatory cytokines directly inhibit the proliferation of erythroid progenitor cells[103]. Third, proinflammatory cytokines also inhibit erythropoietin synthesis in the kidney, resulting in decreased erythropoiesis[104]. In addition to the main symptoms associated with anemia such as fatigue, weakness, or shortness of breath, decreased availability of oxygen in anemic cancer patients may contribute to systemic metabolic changes, such as alterations in circulating and liver lipid levels, which have been shown to associate with hypoxia in animal models[105].

Platelets are anucleate cells generated in the bone marrow by the megakaryocyte. They contribute to hemostasis but also to cancer pathogenesis by releasing growth factors and cytokines[106]. Thrombocytosis (increased blood platelet count) is common in cancer patients. A recent prospective cohort study in the United Kingdom investigated 1-year cancer incidence in 40000 patients aged ≥ 40 years with thrombocytosis[107]. In that cohort, 11.6% of males and 6.2% of females developed cancer in 1-year follow-up, with CRC and lung cancer as the most common diagnoses[107]. The factors contributing to cancer-associated thrombocytosis include CSF2, CSF3, FGF2 (fibroblast growth factor 2, basic fibroblast growth factor), IL6, and THPO (thrombopoietin)[108]. In cancer patients with systemic inflammation, THPO production in the liver is increased in response to IL6 and other cytokines, resulting in increased platelet production[108,109].

Platelet granules contain a plethora of hemostatic factors (*e.g.*, fibrinogen, VWF), enzymes (*e.g.*, MMP1, MMP2), growth factors (*e.g.*, FGF2, PDGF, VEGF), chemokines (*e.g.*, CXCL8, CCL2, CCL3, CCL5), and cytokines (*e.g.*, IL6, IL7), which are released on platelet activation[110,111]. Reacting to the modified tumor vasculature, platelets can release these factors in the tumor microenvironment, promoting tumor progression. Although platelets lack nucleus, it has been demonstrated that the megakaryocyte packs them with a protein translation machinery that includes ribosomes, initiation and termination factors, miRNAs, and template messenger RNAs (mRNAs)[112]. Moreover, recent studies have indicated that platelets are capable of exchanging nucleic acids and proteins with tumor cells, leading to the concept of tumor-educated platelets, *i.e*., platelets reflecting the properties of tumors and programmed to support tumor growth[21,106]. Highlighting the alterations in platelet mRNA profile in cancer patients, a recent study performed mRNA sequencing of 283 platelet samples and found that tumor-educated platelets distinguished cancer patients from healthy individuals with 96% accuracy, differentiated between six primary tumor types, including CRC, with 71% accuracy, and identified several genetic alterations found in tumors, such as *KRAS* mutation[113].

## *Pre-metastatic niches*

In CRC, metastasis is the major cause of death and the main target organ of metastasis is the liver[114]. The understanding of the biological mechanisms of cancer metastasis is still limited. During the past few decades, it has been established that before metastasis, primary tumors can create a favorable microenvironment, a pre-metastatic niche, at tissue sites for subsequent metastasis. Among the first to describe the phenomenon were Kaplan *et al*[115], who showed that in Lewis lung carcinoma and melanoma mouse models, VEGFR1+ (vascular endothelial growth factor receptor 1) bone marrow-derived progenitor cells homed to tumor-specific pre-metastatic sites before the arrival of tumor cells, supporting the subsequent metastasis. The pre-metastatic niches are composed of stromal components of the distant organs, bone marrow-derived cells including stromal cells and immunosuppressive immune cells, and tumor-derived secreted factors, such as cytokines, growth factors, and extracellular vesicles[5,116]. Liu and Cao recently proposed that six hallmark characteristics of pre-metastatic niche include inflammation supporting a proliferatory microenvironment; immunosuppression; angiogenesis; lymphangiogenesis; metabolic, stromal, and epigenetic reprogramming; and organotropism.

Several studies have demonstrated pre-metastatic niches in CRC mouse models. Seubert *et al*[117] found that high systemic TIMP1 levels led to increased hepatic levels of neutrophil chemokine CXCL12, resulting in recruitment of neutrophils to the liver. Both inhibition of CXCL12-mediated neutrophil recruitment and systemic depletion of neutrophils reduced TIMP1-induced increased liver susceptibility towards metastasis. In another study, Shao *et al*[118] showed that CRC-derived small extracellular vesicles, also known as exosomes, are targeted to the liver where they promote the formation of premetastatic niche and CRC metastasis. Liver macrophages, Kupffer cells, engulfed these exosomes and their cargo, leading to Kupffer cell polarization toward proinflammatory phenotype and increased CSF3 and IL6 expression. An inflammatory microenvironment was created and expression of apoptosis and matrix remodeling related genes was altered, promoting cancer metastasis to the liver.

In a mouse model of pancreatic cancer, Lee *et al*[119] showed that IL6, produced by tumor-adjacent non-cancerous fibroblasts, traveled to the liver and mediated STAT3 signaling in hepatocytes, resulting in the secretion of acute phase reactants serum amyloid A1 and A2 (SAA proteins). SAA proteins attracted immunosuppressive myeloid cells to the liver, promoted hepatic stellate cell activation and production of extracellular matrix, creating a metastasis-prone environment in the liver. This study also reported enhanced hepatic SAA expression in CRC patients. All in all, more and more evidence supports the role of systemic inflammation in creating a tumor-favoring environment in distant organs, enabling metastatic tumor cells to survive after colonization.

***Gut microbiome and systemic inflammation***

The large bowel is the dwelling place for a vast set of commensal micro-organisms, mainly bacteria and fungi. Collectively, these are often described as intestinal microbiome or microbiota. Changes in the intestinal microbiota are observed in many situations, including CRC and cachexia[120,121]. The interplay between microbiota and the immune system has gained increasing interest, although our knowledge is still very limited. Still, recent studies have shown that the gut microbiota is able to modulate patients’ responsiveness to PD1 and CTLA4 blocking immunotherapies[122,123]. Such findings give us a glimpse of the potential significance of microbiota to its host.

In normal circumstances, intestinal bacteria are barred from entering the circulation by several mechanisms, collectively known as the intestinal barrier. Increased permeability of the mucosa allows the entry of bacteria or bacterial components into the portal circulation and subsequently, the liver, where they elicit a succinct response[124]. In mouse cancer models, strong correlation exists between circulating IL6 levels and intestinal permeability[121,125]. Animal models of colon cancer have also indicated that areas adjacent to cancer present a disrupted barrier function[126,127], and that systemic inflammation may induce endotoxemia often associated with cancer. Besides bacteria or bacterial components, also bacterial metabolites such as short-chain fatty acids (SCFAs) can modulate peripheral immune response. SCFAs are capable of shifting the effector T to regulatory T cell balance by facilitating the differentiation of regulatory T cells, and thereby limit the systemic inflammation [128].

## *Skeletal muscle, cancer cachexia, and amino acid metabolism*

The international consensus definition of cachexia is an ongoing loss of skeletal muscle mass – with or without loss of fat mass – that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment[129]. Systemic inflammation is a key driving factor in cancer-associated cachexia[16]. In CRC patients, the presence of systemic inflammation is associated with low skeletal muscle mass[130,131]. Cachexia not only reduces patient’s quality of life and treatment response, but it is also an indirect cause of death in about 20% of patients who eventually die of cancer[16].

The ApcMin/+ mouse is a widely used animal model of CRC and CRC-associated cachexia[132]. In this mouse line, the cachexia progression is associated with increased plasma IL6 levels, and cachexia does not progress in the absence of IL6 despite the presence of intestinal and colon tumors[133]. However, in control mice, the overexpression of IL6 does not induce cachexia[133], suggesting that IL6 is an indispensable but not sufficient factor in cancer cachexia pathogenesis. Systemic inflammation in the absence of malignancy, such as in sepsis, is also able to induce severe muscle wasting[134], verifying that active inflammatory reaction is an important driver in muscle catabolism.

Active immune response is a highly energy-consuming process[135,136]. Thus, activation of systemic inflammation in cancer patients requires the utilization of stored energy and nutrients, especially as anorexia is a common symptom in cancer patients with advanced disease. Recently, we investigated the relationships between systemic inflammatory markers and circulating levels of nine amino acids in 336 CRC patients and found that, of the studied factors, systemic inflammation was the main determinant of low serum glutamine level in these patients[137]. Glutamine is the most abundant amino acid in the body, and circulating glutamine is mainly derived from skeletal muscle, functioning as an inter-organ carbon, nitrogen and energy transporter to be utilized by rapidly dividing cells such as enterocytes and lymphocytes[138]. In healthy humans, circulating glutamine is mainly consumed in the gut and kidney[138]. Tumor tissue can either consume or produce glutamine, depending on tissue of origin and oncogene activation[139]. Patients with sepsis have decreased plasma glutamine levels[140] resulting from increased glutamine consumption[141]. Mouse studies have shown that tumor induces a decrease in circulating glutamine levels, stimulates glutamine release and decreases the glutamine content in skeletal muscle[142]. Accordingly, it has been suggested that altered interorgan glutamine homeostasis in cancer patients is an essential driver in cachexia.

# PROGNOSTIC SIGNIFICANCE OF SYSTEMIC INFLAMMATION AND ASSOCIATED PARAMETERS IN CRC

The prognostic and predictive classification of CRC has mainly been based on tumor stage[143,144]. However, each patient and tumor is unique[145], and a more exact classification of the disease based on the features of the tumor and host could enable more personalized treatments. Indeed, patient selection for anti-EGFR treatment for metastatic CRC is currently based on *RAS* and *BRAF* mutation testing[146], and anti-PD1 antibody treatment has been approved for metastatic CRC with high-level microsatellite instability or mismatch repair deficiency[147]. Considering the impact of systemic inflammation in CRC progression, systemic inflammatory markers represent potential additional prognostic and predictive parameters (Table 5).

Acute phase proteins, including CRP, albumin, and their composite mGPS (mGPS0: serum CRP ≤ 10 mg/L and serum albumin ≥ 35 g/L or < 35 g/L; mGPS1: serum CRP > 10 mg/L and serum albumin ≥ 35 g/L; mGPS2: serum CRP > 10 mg/L and serum albumin < 35 g/L), are among the best-studied systemic inflammation-based prognostic parameters in CRC[10]. Numerous studies have reported that high circulating CRP levels, low albumin levels and high mGPS are associated with adverse patient outcome (Table 5). In addition, blood differential leukocyte count parameters have well-established prognostic value in CRC. Myeloid cell proliferation, associated with systemic response to CRC, leads to an increase in circulating neutrophil and monocyte counts, relative to lymphocytes, which has been associated with adverse outcome[148,149]. Indices based on relative counts of these cell types represent promising prognostic parameters. Preoperative anemia, reflecting systemic inflammation in a subset of patients, has also been associated with adverse outcome[150]. Platelet count and platelet-to-lymphocyte ratio can also provide potentially clinically relevant prognostic information[151–153], with high platelet counts associated with poor survival. In future, more sophisticated analyses of platelet composition and function, such as platelet RNA sequencing, may complement these parameters to provide more nuanced information of the status of platelet activation and education during systemic inflammation[21].

Several studies have indicated that circulating cytokine concentrations provide prognostic information in CRC. Recently, using proximity extension assays, Birgisson *et al*[20] analyzed plasma levels of 92 oncology-related proteins, including an assemblage of cytokines, chemokines, and growth factors, in a cohort of 261 stage II-IV CRC patients. Many of these molecules, including CSF1, CXCL10, CXCL9, HGF (hepatocyte growth factor), IL6, osteoprotegerin, PGF (placental growth factor), and VEGFA, were significantly associated with survival in univariable analysis, and of these, osteoprotegerin was the best in predicting survival in multivariable survival models[20]. Analyzing multiple markers in one sample may improve the prognostic power relative to measuring the levels of a single marker. However, caution needs to be employed when interpreting the results of such studies because of the well-known risk of multiple hypothesis testing, necessitating confirmation of the findings in independent study populations. As indicated by a recent meta-analysis[154], a few multiple cytokine array studies have been conducted in CRC, but mainly in fairly small populations, with varying markers and methods, making further larger scale studies necessary to draw more convincing conclusion about the prognostic significance of the reported marker combinations.

During the past decade, increasing effort has been directed towards the investigation of circulating tumor-derived extracellular vesicles as potential prognostic and diagnostic biomarkers in CRC and other tumors. Based on this approach, several promising results have been reported. For example, Liu *et al*[22] recently studied circulating exosomal miRNA content from 369 stage I–IV CRC patients. They found that exosomal miR-27a and miR-130a predicted survival. However, as for multiplex cytokine arrays, the selection of optimal combination of markers as well as independent validation studies would be required to establish circulating exosomal miRNA signatures as clinically relevant prognostic parameters in CRC.

# CONCLUSION

The research conducted during the past few decades indicates that systemic inflammation has wide-ranging effects on CRC progression, including supporting primary tumor invasion, proliferation, angiogenesis, and metastasis, as well as suppressing anti-tumor immunity. Several systemic inflammation-based prognostic parameters, such as neutrophil-lymphocyte ratio, modified Glasgow Prognostic Score, and platelet-lymphocyte ratio, have been found to have impressive prognostic value in a large number of studies and are widely available in clinical laboratories worldwide. However, larger-scale multi-institutional studies of their predictive value for the response to specific adjuvant therapies are needed. Moreover, these markers only begin to scratch the surface of the potential of systemic inflammation-based biomarkers in predicting patient survival. In future, additional tests, such as multiple cytokine-chemokine-growth factor assays, analysis of tumor-derived extracellular vesicles, and profiling of tumor-educated platelet transcriptome may translate into improved prognostic and predictive parameters, ultimately enabling accurate identification of patients who might benefit from specific adjuvant therapies, as well as into improved methods of non-invasive disease monitoring. Factors regulating the formation of pre-metastatic niches in CRC, suppression of anti-tumor immunity, tumor-platelet interactions, and CRC-associated cachexia also represent potential targets for drug development.

# REFERENCES

1 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

2 **McAllister SS**, Weinberg RA. Tumor-host interactions: a far-reaching relationship. *J Clin Oncol* 2010; **28**: 4022-4028 [PMID: 20644094 DOI: 10.1200/JCO.2010.28.4257]

3 **Schreiber RD**, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 2011; **331**: 1565-1570 [PMID: 21436444 DOI: 10.1126/science.1203486]

4 **Balkwill FR**, Capasso M, Hagemann T. The tumor microenvironment at a glance. *J Cell Sci* 2012; **125**: 5591-5596 [PMID: 23420197 DOI: 10.1242/jcs.116392]

5 **McAllister SS**, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. *Nat Cell Biol* 2014; **16**: 717-727 [PMID: 25082194 DOI: 10.1038/ncb3015]

6 **Dolan RD**, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. *Crit Rev Oncol Hematol* 2017; **116**: 134-146 [PMID: 28693795 DOI: 10.1016/j.critrevonc.2017.06.002]

7 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

8 **Park JH**, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. *Ann Surg* 2016; **263**: 326-336 [PMID: 25575264 DOI: 10.1097/SLA.0000000000001122]

9 **Kantola T**, Klintrup K, Väyrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Näpänkangas J, Mäkelä J, Karttunen TJ, Tuomisto A, Mäkinen MJ. Reply: Comment on 'Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma'. *Br J Cancer* 2013; **108**: 1917-1918 [PMID: 23579221 DOI: 10.1038/bjc.2013.162]

10 **McMillan DC**. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. *Cancer Treat Rev* 2013; **39**: 534-540 [PMID: 22995477 DOI: 10.1016/j.ctrv.2012.08.003]

11 **Ding PR**, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. *Int J Colorectal Dis* 2010; **25**: 1427-1433 [PMID: 20821217 DOI: 10.1007/s00384-010-1052-0]

12 **Dolan RD**, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. *Sci Rep* 2017; **7**: 16717 [PMID: 29196718 DOI: 10.1038/s41598-017-16955-5]

13 **Haram A**, Boland MR, Kelly ME, Bolger JC, Waldron RM, Kerin MJ. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review. *J Surg Oncol* 2017; **115**: 470-479 [PMID: 28105646 DOI: 10.1002/jso.24523]

14 **Park JH**, van Wyk H, Roxburgh CSD, Horgan PG, Edwards J, McMillan DC. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. *Br J Cancer* 2017; **116**: 1444-1450 [PMID: 28427085 DOI: 10.1038/bjc.2017.108]

15 **Gabay C**, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 1999; **340**: 448-454 [PMID: 9971870 DOI: 10.1056/NEJM199902113400607]

16 **Argilés JM**, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. *Nat Rev Cancer* 2014; **14**: 754-762 [PMID: 25291291 DOI: 10.1038/nrc3829]

17 **Roxburgh CS**, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. *Br J Cancer* 2014; **110**: 1409-1412 [PMID: 24548867 DOI: 10.1038/bjc.2014.90]

18 **Kantola T**, Klintrup K, Väyrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Näpänkangas J, Mäkelä J, Karttunen TJ, Tuomisto A, Mäkinen MJ. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. *Br J Cancer* 2012; **107**: 1729-1736 [PMID: 23059742 DOI: 10.1038/bjc.2012.456]

19 **Chen ZY**, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. *Br J Cancer* 2015; **112**: 1088-1097 [PMID: 25688736 DOI: 10.1038/bjc.2015.61]

20 **Birgisson H**, Tsimogiannis K, Freyhult E, Kamali-Moghaddam M. Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer. *Transl Oncol* 2018; **11**: 1034-1043 [PMID: 29982101 DOI: 10.1016/j.tranon.2018.05.012]

21 **Best MG**, Wesseling P, Wurdinger T. Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring. *Cancer Res* 2018; **78**: 3407-3412 [PMID: 29921699 DOI: 10.1158/0008-5472.CAN-18-0887]

22 **Liu X**, Pan B, Sun L, Chen X, Zeng K, Hu X, Xu T, Xu M, Wang S. Circulating Exosomal miR-27a and miR-130a Act as Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev* 2018; **27**: 746-754 [PMID: 29739748 DOI: 10.1158/1055-9965.EPI-18-0067]

23 **Xu J**, Ye Y, Zhang H, Szmitkowski M, Mäkinen MJ, Li P, Xia D, Yang J, Wu Y, Wu H. Diagnostic and Prognostic Value of Serum Interleukin-6 in Colorectal Cancer. *Medicine (Baltimore)* 2016; **95**: e2502 [PMID: 26765465 DOI: 10.1097/MD.0000000000002502]

24 **Jin WJ**, Xu JM, Xu WL, Gu DH, Li PW. Diagnostic value of interleukin-8 in colorectal cancer: a case-control study and meta-analysis. *World J Gastroenterol* 2014; **20**: 16334-16342 [PMID: 25473192 DOI: 10.3748/wjg.v20.i43.16334]

25 **Liu Z**, Zhang Y, Niu Y, Li K, Liu X, Chen H, Gao C. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. *PLoS One* 2014; **9**: e103910 [PMID: 25105762 DOI: 10.1371/journal.pone.0103910]

26 **Fukuyama T**, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, Mizukami M, Sugaya M, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. *Cancer Sci* 2007; **98**: 1048-1054 [PMID: 17511773 DOI: 10.1111/j.1349-7006.2007.00507.x]

27 **Tao L**, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: An essential role in the tumor microenvironment. *Oncol Lett* 2017; **14**: 2611-2620 [PMID: 28927027 DOI: 10.3892/ol.2017.6497]

28 **Guerriero JL**. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. *Trends Mol Med* 2018; **24**: 472-489 [PMID: 29655673 DOI: 10.1016/j.molmed.2018.03.006]

29 **Nagasaki T**, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. *Br J Cancer* 2014; **110**: 469-478 [PMID: 24346288 DOI: 10.1038/bjc.2013.748]

30 **Xiao YC**, Yang ZB, Cheng XS, Fang XB, Shen T, Xia CF, Liu P, Qian HH, Sun B, Yin ZF, Li YF. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. *Cancer Lett* 2015; **361**: 22-32 [PMID: 25687885 DOI: 10.1016/j.canlet.2015.02.021]

31 **Waldner MJ**, Foersch S, Neurath MF. Interleukin-6--a key regulator of colorectal cancer development. *Int J Biol Sci* 2012; **8**: 1248-1253 [PMID: 23136553 DOI: 10.7150/ijbs.4614]

32 **Qian BZ**, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature* 2011; **475**: 222-225 [PMID: 21654748 DOI: 10.1038/nature10138]

33 **Heidemann J**, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, Otterson MF, Ota DM, Lugering N, Domschke W, Binion DG. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. *J Biol Chem* 2003; **278**: 8508-8515 [PMID: 12496258 DOI: 10.1074/jbc.M208231200]

34 **Hamilton TA**, Zhao C, Pavicic PG Jr, Datta S. Myeloid colony-stimulating factors as regulators of macrophage polarization. *Front Immunol* 2014; **5**: 554 [PMID: 25484881 DOI: 10.3389/fimmu.2014.00554]

35 **Manning S**, Danielson KM. The immunomodulatory role of tumor-derived extracellular vesicles in colorectal cancer. *Immunol Cell Biol* 2018 [PMID: 29575270 DOI: 10.1111/imcb.12038]

36 **Becker A**, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. *Cancer Cell* 2016; **30**: 836-848 [PMID: 27960084 DOI: 10.1016/j.ccell.2016.10.009]

37 **Yamada N**, Kuranaga Y, Kumazaki M, Shinohara H, Taniguchi K, Akao Y. Colorectal cancer cell-derived extracellular vesicles induce phenotypic alteration of T cells into tumor-growth supporting cells with transforming growth factor-β1-mediated suppression. *Oncotarget* 2016; **7**: 27033-27043 [PMID: 27081032 DOI: 10.18632/oncotarget.7041]

38 **Chen Y**, Xie Y, Xu L, Zhan S, Xiao Y, Gao Y, Wu B, Ge W. Protein content and functional characteristics of serum-purified exosomes from patients with colorectal cancer revealed by quantitative proteomics. *Int J Cancer* 2017; **140**: 900-913 [PMID: 27813080 DOI: 10.1002/ijc.30496]

39 **Alfonsi R**, Grassi L, Signore M, Bonci D. The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation. *Int J Mol Sci* 2018; **19**: [PMID: 29652798 DOI: 10.3390/ijms19041183]

40 **Väyrynen JP**, Tuomisto A, Klintrup K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. *Br J Cancer* 2013; **109**: 1839-1847 [PMID: 24008661 DOI: 10.1038/bjc.2013.508]

41 **Bindea G**, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013; **39**: 782-795 [PMID: 24138885 DOI: 10.1016/j.immuni.2013.10.003]

42 **Klintrup K**, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Inflammation and prognosis in colorectal cancer. *Eur J Cancer* 2005; **41**: 2645-2654 [PMID: 16239109 DOI: 10.1016/j.ejca.2005.07.017]

43 **Jass JR**, Love SB, Northover JM. A new prognostic classification of rectal cancer. *Lancet* 1987; **1**: 1303-1306 [PMID: 2884421]

44 **Väyrynen JP**, Sajanti SA, Klintrup K, Mäkelä J, Herzig KH, Karttunen TJ, Tuomisto A, Mäkinen MJ. Characteristics and significance of colorectal cancer associated lymphoid reaction. *Int J Cancer* 2014; **134**: 2126-2135 [PMID: 24154855 DOI: 10.1002/ijc.28533]

45 **Ogino S**, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. *Clin Cancer Res* 2009; **15**: 6412-6420 [PMID: 19825961 DOI: 10.1158/1078-0432.CCR-09-1438]

46 **Väyrynen JP**, Vornanen JO, Sajanti S, Böhm JP, Tuomisto A, Mäkinen MJ. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. *Virchows Arch* 2012; **460**: 455-465 [PMID: 22527018 DOI: 10.1007/s00428-012-1232-0]

47 **Wirta EV**, Seppälä T, Friman M, Väyrynen J, Ahtiainen M, Kautiainen H, Kuopio T, Kellokumpu I, Mecklin JP, Böhm J. Immunoscore in mismatch repair-proficient and -deficient colon cancer. *J Pathol Clin Res* 2017; **3**: 203-213 [PMID: 28770104 DOI: 10.1002/cjp2.71]

48 **Pagès F**, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* 2018; **391**: 2128-2139 [PMID: 29754777 DOI: 10.1016/S0140-6736(18)30789-X]

49 **Pagès F**, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. *N Engl J Med* 2005; **353**: 2654-2666 [PMID: 16371631 DOI: 10.1056/NEJMoa051424]

50 **Forssell J**, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. *Clin Cancer Res* 2007; **13**: 1472-1479 [PMID: 17332291 DOI: 10.1158/1078-0432.CCR-06-2073]

51 **Dunn GP**, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev Immunol* 2004; **22**: 329-360 [PMID: 15032581 DOI: 10.1146/annurev.immunol.22.012703.104803]

52 **Tosolini M**, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. *Cancer Res* 2011; **71**: 1263-1271 [PMID: 21303976 DOI: 10.1158/0008-5472.CAN-10-2907]

53 **Turner N**, Wong HL, Templeton A, Tripathy S, Whiti Rogers T, Croxford M, Jones I, Sinnathamby M, Desai J, Tie J, Bae S, Christie M, Gibbs P, Tran B. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. *Int J Cancer* 2016; **138**: 671-678 [PMID: 26270488 DOI: 10.1002/ijc.29805]

54 **Murray PJ**, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 2014; **41**: 14-20 [PMID: 25035950 DOI: 10.1016/j.immuni.2014.06.008]

55 **Zhu J**, Paul WE. Heterogeneity and plasticity of T helper cells. *Cell Res* 2010; **20**: 4-12 [PMID: 20010916 DOI: 10.1038/cr.2009.138]

56 **Lund FE**. Cytokine-producing B lymphocytes-key regulators of immunity. *Curr Opin Immunol* 2008; **20**: 332-338 [PMID: 18417336 DOI: 10.1016/j.coi.2008.03.003]

57 **Bird L**. Tumour immunology: Neutrophil plasticity. *Nat Rev Immunol* 2009; **9**: 672 [DOI: 10.1038/nri2649]

58 **Tecchio C**, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. *Front Immunol* 2014; **5**: 508 [PMID: 25374568 DOI: 10.3389/fimmu.2014.00508]

59 **Fridlender ZG**, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. *Cancer Cell* 2009; **16**: 183-194 [PMID: 19732719 DOI: 10.1016/j.ccr.2009.06.017]

60 **Eruslanov EB**, Singhal S, Albelda SM. Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap. *Trends Cancer* 2017; **3**: 149-160 [PMID: 28718445 DOI: 10.1016/j.trecan.2016.12.006]

61 **Tommelein J**, De Vlieghere E, Verset L, Melsens E, Leenders J, Descamps B, Debucquoy A, Vanhove C, Pauwels P, Gespach CP, Vral A, De Boeck A, Haustermans K, de Tullio P, Ceelen W, Demetter P, Boterberg T, Bracke M, De Wever O. Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation. *Cancer Res* 2018; **78**: 659-670 [PMID: 29217764 DOI: 10.1158/0008-5472.CAN-17-0524]

62 **Huynh PT**, Beswick EJ, Coronado YA, Johnson P, O'Connell MR, Watts T, Singh P, Qiu S, Morris K, Powell DW, Pinchuk IV. CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer. *Int J Cancer* 2016; **138**: 1971-1981 [PMID: 26595254 DOI: 10.1002/ijc.29939]

63 **De Boeck A**, Hendrix A, Maynard D, Van Bockstal M, Daniëls A, Pauwels P, Gespach C, Bracke M, De Wever O. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. *Proteomics* 2013; **13**: 379-388 [PMID: 23175172 DOI: 10.1002/pmic.201200179]

64 **Van Lint P**, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. *Cytokine Growth Factor Rev* 2006; **17**: 217-223 [PMID: 16820317 DOI: 10.1016/j.cytogfr.2006.04.001]

65 **Cathcart J**, Pulkoski-Gross A, Cao J. Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. *Genes Dis* 2015; **2**: 26-34 [PMID: 26097889 DOI: 10.1016/j.gendis.2014.12.002]

66 **Tauriello DVF**, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, Byrom D, Matarin JA, Calon A, Rivas EI, Nebreda AR, Riera A, Attolini CS, Batlle E. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* 2018; **554**: 538-543 [PMID: 29443964 DOI: 10.1038/nature25492]

67 **Ros XR**, Vermeulen L. Turning Cold Tumors Hot by Blocking TGF-β. *Trends Cancer* 2018; **4**: 335-337 [PMID: 29709256 DOI: 10.1016/j.trecan.2018.03.005]

68 **Hawinkels LJ**, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K, Koelink PJ, Lindeman JH, Mesker W, ten Dijke P, Sier CF. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. *Oncogene* 2014; **33**: 97-107 [PMID: 23208491 DOI: 10.1038/onc.2012.536]

69 **Richards CH**, Roxburgh CS, Anderson JH, McKee RF, Foulis AK, Horgan PG, McMillan DC. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. *Br J Surg* 2012; **99**: 287-294 [PMID: 22086662 DOI: 10.1002/bjs.7755]

70 **Väyrynen SA**, Väyrynen JP, Klintrup K, Mäkelä J, Karttunen TJ, Tuomisto A, Mäkinen MJ. Clinical impact and network of determinants of tumour necrosis in colorectal cancer. *Br J Cancer* 2016; **114**: 1334-1342 [PMID: 27195424 DOI: 10.1038/bjc.2016.128]

71 **Pollheimer MJ**, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P, Langner C. Tumor necrosis is a new promising prognostic factor in colorectal cancer. *Hum Pathol* 2010; **41**: 1749-1757 [PMID: 20869096 DOI: 10.1016/j.humpath.2010.04.018]

72 **Chen CJ**, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. *Nat Med* 2007; **13**: 851-856 [PMID: 17572686 DOI: 10.1038/nm1603]

73 **Zhang Q**, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* 2010; **464**: 104-107 [PMID: 20203610 DOI: 10.1038/nature08780]

74 **Väyrynen JP**, Mutt SJ, Herzig KH, Väyrynen SA, Kantola T, Karhu T, Karttunen TJ, Klintrup K, Mäkelä J, Mäkinen MJ, Tuomisto A. Decreased preoperative serum 25-Hydroxyvitamin D levels in colorectal cancer are associated with systemic inflammation and serrated morphology. *Sci Rep* 2016; **6**: 36519 [PMID: 27819306 DOI: 10.1038/srep36519]

75 **Guthrie GJ**, Roxburgh CS, Richards CH, Horgan PG, McMillan DC. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. *Br J Cancer* 2013; **109**: 131-137 [PMID: 23756867 DOI: 10.1038/bjc.2013.291]

76 **Bousquet PA**, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. *Transl Oncol* 2019; **12**: 76-83 [PMID: 30273860 DOI: 10.1016/j.tranon.2018.09.010]

77 **Peinado H**, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, Bissell MJ, Cox TR, Giaccia AJ, Erler JT, Hiratsuka S, Ghajar CM, Lyden D. Pre-metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer* 2017; **17**: 302-317 [PMID: 28303905 DOI: 10.1038/nrc.2017.6]

78 **Trefts E**, Gannon M, Wasserman DH. The liver. *Curr Biol* 2017; **27**: R1147-R1151 [PMID: 29112863 DOI: 10.1016/j.cub.2017.09.019]

79 **Robinson MW**, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. *Cell Mol Immunol* 2016; **13**: 267-276 [PMID: 27063467 DOI: 10.1038/cmi.2016.3]

80 **Naugler WE**, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol Med* 2008; **14**: 109-119 [PMID: 18261959 DOI: 10.1016/j.molmed.2007.12.007]

81 **Flint TR**, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. *Cell Metab* 2016; **24**: 672-684 [PMID: 27829137 DOI: 10.1016/j.cmet.2016.10.010]

82 **Orkin SH**, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell* 2008; **132**: 631-644 [PMID: 18295580 DOI: 10.1016/j.cell.2008.01.025]

83 **Mirantes C**, Passegué E, Pietras EM. Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis. *Exp Cell Res* 2014; **329**: 248-254 [PMID: 25149680 DOI: 10.1016/j.yexcr.2014.08.017]

84 **Wu WC**, Sun HW, Chen HT, Liang J, Yu XJ, Wu C, Wang Z, Zheng L. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. *Proc Natl Acad Sci U S A* 2014; **111**: 4221-4226 [PMID: 24591638 DOI: 10.1073/pnas.1320753111]

85 **Stojkovic Lalosevic M**, Pavlovic Markovic A, Stankovic S, Stojkovic M, Dimitrijevic I, Radoman Vujacic I, Lalic D, Milovanovic T, Dumic I, Krivokapic Z. Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer. *Dis Markers* 2019; **2019**: 6036979 [PMID: 30800188 DOI: 10.1155/2019/6036979]

86 **Marigo I**, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. *Immunol Rev* 2008; **222**: 162-179 [PMID: 18364001 DOI: 10.1111/j.1600-065X.2008.00602.x]

87 **Bronte V**, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun* 2016; **7**: 12150 [PMID: 27381735 DOI: 10.1038/ncomms12150]

88 **Ostrand-Rosenberg S**, Sinha P, Chornoguz O, Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). *Cancer Immunol Immunother* 2012; **61**: 1319-1325 [PMID: 22546994 DOI: 10.1007/s00262-012-1269-6]

89 **OuYang LY**, Wu XJ, Ye SB, Zhang RX, Li ZL, Liao W, Pan ZZ, Zheng LM, Zhang XS, Wang Z, Li Q, Ma G, Li J. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. *J Transl Med* 2015; **13**: 47 [PMID: 25638150 DOI: 10.1186/s12967-015-0410-7]

90 **Elliott LA**, Doherty GA, Sheahan K, Ryan EJ. Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. *Front Immunol* 2017; **8**: 86 [PMID: 28220123 DOI: 10.3389/fimmu.2017.00086]

91 **De Veirman K**, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. *Front Oncol* 2014; **4**: 349 [PMID: 25538893 DOI: 10.3389/fonc.2014.00349]

92 **Munder M**. Arginase: an emerging key player in the mammalian immune system. *Br J Pharmacol* 2009; **158**: 638-651 [PMID: 19764983 DOI: 10.1111/j.1476-5381.2009.00291.x]

93 **Labadie BW**, Bao R, Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. *Clin Cancer Res* 2019; **25**: 1462-1471 [PMID: 30377198 DOI: 10.1158/1078-0432.ccr-18-2882]

94 **Väyrynen JP**, Tuomisto A, Mäkinen MJ. Regulatory mechanisms of T cell activation-From basic research discoveries to a new principle of cancer therapy and the Nobel Prize. *Acta Physiol (Oxf)* 2019; **225**: e13224 [PMID: 30471201 DOI: 10.1111/apha.13224]

95 **Ballbach M**, Dannert A, Singh A, Siegmund DM, Handgretinger R, Piali L, Rieber N, Hartl D. Expression of checkpoint molecules on myeloid-derived suppressor cells. *Immunol Lett* 2017; **192**: 1-6 [PMID: 28987474 DOI: 10.1016/j.imlet.2017.10.001]

96 **Freeman GJ**, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000; **192**: 1027-1034 [PMID: 11015443 DOI: 10.1084/jem.192.7.1027]

97 **McSorley ST**, Johnstone M, Steele CW, Roxburgh CSD, Horgan PG, McMillan DC, Mansouri D. Normocytic anaemia is associated with systemic inflammation and poorer survival in patients with colorectal cancer treated with curative intent. *Int J Colorectal Dis* 2019; **34**: 401-408 [PMID: 30515556 DOI: 10.1007/s00384-018-3211-7]

98 **Väyrynen JP**, Tuomisto A, Väyrynen SA, Klintrup K, Karhu T, Mäkelä J, Herzig KH, Karttunen TJ, Mäkinen MJ. Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival. *Sci Rep* 2018; **8**: 1126 [PMID: 29348549 DOI: 10.1038/s41598-018-19572-y]

99 **McSorley ST**, Tham A, Steele CW, Dolan RD, Roxburgh CS, Horgan PG, McMillan DC. Quantitative data on red cell measures of iron status and their relation to the magnitude of the systemic inflammatory response and survival in patients with colorectal cancer. *Eur J Surg Oncol* 2019; **45**: 1205-1211 [PMID: 30850153 DOI: 10.1016/j.ejso.2019.02.027]

100 **Zorzi M**, Fedato C, Grazzini G, Stocco FC, Banovich F, Bortoli A, Cazzola L, Montaguti A, Moretto T, Zappa M, Vettorazzi M. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. *Gut* 2011; **60**: 944-949 [PMID: 21193461 DOI: 10.1136/gut.2010.223982]

101 **Roy CN**, Andrews NC. Anemia of inflammation: the hepcidin link. *Curr Opin Hematol* 2005; **12**: 107-111 [PMID: 15725899]

102 **Weiss G**, Ganz T, Goodnough LT. Anemia of inflammation. *Blood* 2019; **133**: 40-50 [PMID: 30401705 DOI: 10.1182/blood-2018-06-856500]

103 **Weiss G**, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005; **352**: 1011-1023 [PMID: 15758012 DOI: 10.1056/NEJMra041809]

104 **Spivak JL**. The anaemia of cancer: death by a thousand cuts. *Nat Rev Cancer* 2005; **5**: 543-555 [PMID: 15965494 DOI: 10.1038/nrc1648]

105 **Siques P**, Brito J, Naveas N, Pulido R, De la Cruz JJ, Mamani M, León-Velarde F. Plasma and liver lipid profiles in rats exposed to chronic hypobaric hypoxia: changes in metabolic pathways. *High Alt Med Biol* 2014; **15**: 388-395 [PMID: 25185022 DOI: 10.1089/ham.2013.1134]

106 **Joosse SA**, Pantel K. Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. *Cancer Cell* 2015; **28**: 552-554 [PMID: 26555171 DOI: 10.1016/j.ccell.2015.10.007]

107 **Bailey SE**, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. *Br J Gen Pract* 2017; **67**: e405-e413 [PMID: 28533199 DOI: 10.3399/bjgp17X691109]

108 **Plantureux L**, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. *Cancers (Basel)* 2018; **10**: [PMID: 30441823 DOI: 10.3390/cancers10110441]

109 **Schafer AI**. Thrombocytosis. *N Engl J Med* 2004; **350**: 1211-1219 [PMID: 15028825 DOI: 10.1056/NEJMra035363]

110 **Blair P**, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. *Blood Rev* 2009; **23**: 177-189 [PMID: 19450911 DOI: 10.1016/j.blre.2009.04.001]

111 **Whiteheart SW**. Platelet granules: surprise packages. *Blood* 2011; **118**: 1190-1191 [PMID: 21816838 DOI: 10.1182/blood-2011-06-359836]

112 **Rowley JW**, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the message. *Curr Opin Hematol* 2012; **19**: 385-391 [PMID: 22814651 DOI: 10.1097/MOH.0b013e328357010e]

113 **Best MG**, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B, Ameziane N, Dorsman J, Smit EF, Verheul HM, Noske DP, Reijneveld JC, Nilsson RJA, Tannous BA, Wesseling P, Wurdinger T. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. *Cancer Cell* 2015; **28**: 666-676 [PMID: 26525104 DOI: 10.1016/j.ccell.2015.09.018]

114 **Hugen N**, Nagtegaal ID. Distinct metastatic patterns in colorectal cancer patients based on primary tumour location. *Eur J Cancer* 2017; **75**: 3-4 [PMID: 28214423 DOI: 10.1016/j.ejca.2017.01.003]

115 **Kaplan RN**, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005; **438**: 820-827 [PMID: 16341007 DOI: 10.1038/nature04186]

116 **Liu Y**, Cao X. Characteristics and Significance of the Pre-metastatic Niche. *Cancer Cell* 2016; **30**: 668-681 [PMID: 27846389 DOI: 10.1016/j.ccell.2016.09.011]

117 **Seubert B**, Grünwald B, Kobuch J, Cui H, Schelter F, Schaten S, Siveke JT, Lim NH, Nagase H, Simonavicius N, Heikenwalder M, Reinheckel T, Sleeman JP, Janssen KP, Knolle PA, Krüger A. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. *Hepatology* 2015; **61**: 238-248 [PMID: 25131778 DOI: 10.1002/hep.27378]

118 **Shao Y**, Chen T, Zheng X, Yang S, Xu K, Chen X, Xu F, Wang L, Shen Y, Wang T, Zhang M, Hu W, Ye C, Yu X, Shao J, Zheng S. Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. *Carcinogenesis* 2018; **39**: 1368-1379 [PMID: 30184100 DOI: 10.1093/carcin/bgy115]

119 **Lee JW**, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL. Hepatocytes direct the formation of a pro-metastatic niche in the liver. *Nature* 2019; **567**: 249-252 [PMID: 30842658 DOI: 10.1038/s41586-019-1004-y]

120 **Tilg H**, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell* 2018; **33**: 954-964 [PMID: 29657127 DOI: 10.1016/j.ccell.2018.03.004]

121 **Bindels LB**, Neyrinck AM, Loumaye A, Catry E, Walgrave H, Cherbuy C, Leclercq S, Van Hul M, Plovier H, Pachikian B, Bermúdez-Humarán LG, Langella P, Cani PD, Thissen JP, Delzenne NM. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. *Oncotarget* 2018; **9**: 18224-18238 [PMID: 29719601 DOI: 10.18632/oncotarget.24804]

122 **Routy B**, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science* 2018; **359**: 91-97 [PMID: 29097494 DOI: 10.1126/science.aan3706]

123 **Vétizou M**, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science* 2015; **350**: 1079-1084 [PMID: 26541610 DOI: 10.1126/science.aad1329]

124 **Invernizzi P**. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. *J Autoimmun* 2013; **46**: 1-6 [PMID: 24012346 DOI: 10.1016/j.jaut.2013.08.006]

125 **Puppa MJ**, White JP, Sato S, Cairns M, Baynes JW, Carson JA. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. *Biochim Biophys Acta* 2011; **1812**: 1601-1606 [PMID: 21914473 DOI: 10.1016/j.bbadis.2011.08.010]

126 **Soler AP**, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM. Increased tight junctional permeability is associated with the development of colon cancer. *Carcinogenesis* 1999; **20**: 1425-1431 [PMID: 10426787 DOI: 10.1093/carcin/20.8.1425]

127 **Bekusova VV**, Falchuk EL, Okorokova LS, Kruglova NM, Nozdrachev AD, Markov AG. Increased paracellular permeability of tumor-adjacent areas in 1,2-dimethylhydrazine-induced colon carcinogenesis in rats. *Cancer Biol Med* 2018; **15**: 251-259 [PMID: 30197792 DOI: 10.20892/j.issn.2095-3941.2018.0016]

128 **Arpaia N**, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013; **504**: 451-455 [PMID: 24226773 DOI: 10.1038/nature12726]

129 **Fearon K**, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011; **12**: 489-495 [PMID: 21296615 DOI: 10.1016/S1470-2045(10)70218-7]

130 **Richards CH**, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG, McMillan DC. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. *PLoS One* 2012; **7**: e41883 [PMID: 22870258 DOI: 10.1371/journal.pone.0041883]

131 **Feliciano EMC**, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, Xiao J, Alexeeff S, Corley D, Weltzien E, Castillo AL, Caan BJ. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. *JAMA Oncol* 2017; **3**: e172319 [PMID: 28796857 DOI: 10.1001/jamaoncol.2017.2319]

132 **Su LK**, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. *Science* 1992; **256**: 668-670 [PMID: 1350108]

133 **Baltgalvis KA**, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. *Am J Physiol Regul Integr Comp Physiol* 2008; **294**: R393-R401 [PMID: 18056981 DOI: 10.1152/ajpregu.00716.2007]

134 **Vary TC**, Kimball SR. Sepsis-induced changes in protein synthesis: differential effects on fast- and slow-twitch muscles. *Am J Physiol* 1992; **262**: C1513-C1519 [PMID: 1377447 DOI: 10.1152/ajpcell.1992.262.6.C1513]

135 **Rauw WM**. Immune response from a resource allocation perspective. *Front Genet* 2012; **3**: 267 [PMID: 23413205 DOI: 10.3389/fgene.2012.00267]

136 **Demas GE**, Chefer V, Talan MI, Nelson RJ. Metabolic costs of mounting an antigen-stimulated immune response in adult and aged C57BL/6J mice. *Am J Physiol* 1997; **273**: R1631-R1637 [PMID: 9374803 DOI: 10.1152/ajpregu.1997.273.5.R1631]

137 **Sirniö P**, Väyrynen JP, Klintrup K, Mäkelä J, Karhu T, Herzig KH, Minkkinen I, Mäkinen MJ, Karttunen TJ, Tuomisto A. Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival. *Br J Cancer* 2019; **120**: 238-246 [PMID: 30563990 DOI: 10.1038/s41416-018-0357-6]

138 **Hensley CT**, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. *J Clin Invest* 2013; **123**: 3678-3684 [PMID: 23999442 DOI: 10.1172/JCI69600]

139 **Yuneva MO**, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, Matés JM, Alonso FJ, Wang C, Seo Y, Chen X, Bishop JM. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. *Cell Metab* 2012; **15**: 157-170 [PMID: 22326218 DOI: 10.1016/j.cmet.2011.12.015]

140 **Kao CC**, Bandi V, Guntupalli KK, Wu M, Castillo L, Jahoor F. Arginine, citrulline and nitric oxide metabolism in sepsis. *Clin Sci (Lond)* 2009; **117**: 23-30 [PMID: 19105791 DOI: 10.1042/CS20080444]

141 **Kao C**, Hsu J, Bandi V, Jahoor F. Alterations in glutamine metabolism and its conversion to citrulline in sepsis. *Am J Physiol Endocrinol Metab* 2013; **304**: E1359-E1364 [PMID: 23612995 DOI: 10.1152/ajpendo.00628.2012]

142 **Chen MK**, Espat NJ, Bland KI, Copeland EM 3rd, Souba WW. Influence of progressive tumor growth on glutamine metabolism in skeletal muscle and kidney. *Ann Surg* 1993; **217**: 655-66; discussion 666-7 [PMID: 8099476 DOI: 10.1097/00000658-199306000-00007]

143 **Schmoll HJ**, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. *Ann Oncol* 2012; **23**: 2479-2516 [PMID: 23012255 DOI: 10.1093/annonc/mds236]

144 **Glynne-Jones R**, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017; **28**: iv22-iv40 [PMID: 28881920 DOI: 10.1093/annonc/mdx224]

145 **Ogino S**, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. *Expert Rev Mol Diagn* 2012; **12**: 621-628 [PMID: 22845482 DOI: 10.1586/erm.12.46]

146 **Van Cutsem E**, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; **27**: 1386-1422 [PMID: 27380959 DOI: 10.1093/annonc/mdw235]

147 **Ogino S**, Nowak JA, Hamada T, Phipps AI, Peters U, Milner DA Jr, Giovannucci EL, Nishihara R, Giannakis M, Garrett WS, Song M. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. *Gut* 2018; **67**: 1168-1180 [PMID: 29437869 DOI: 10.1136/gutjnl-2017-315537]

148 **Li H**, Zhao Y, Zheng F. Prognostic significance of elevated preoperative neutrophil-to-lymphocyte ratio for patients with colorectal cancer undergoing curative surgery: A meta-analysis. *Medicine (Baltimore)* 2019; **98**: e14126 [PMID: 30653142 DOI: 10.1097/MD.0000000000014126]

149 **Tan D**, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis. *Int J Surg* 2018; **55**: 128-138 [PMID: 29807167 DOI: 10.1016/j.ijsu.2018.05.030]

150 **Wilson MJ**, van Haaren M, Harlaar JJ, Park HC, Bonjer HJ, Jeekel J, Zwaginga JJ, Schipperus M. Long-term prognostic value of preoperative anemia in patients with colorectal cancer: A systematic review and meta-analysis. *Surg Oncol* 2017; **26**: 96-104 [PMID: 28317592 DOI: 10.1016/j.suronc.2017.01.005]

151 **Gu D**, Szallasi A. Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies. *Anticancer Res* 2017; **37**: 4717-4726 [PMID: 28870890 DOI: 10.21873/anticanres.11878]

152 **Rao XD**, Zhang H, Xu ZS, Cheng H, Shen W, Wang XP. Poor prognostic role of the pretreatment platelet counts in colorectal cancer: A meta-analysis. *Medicine (Baltimore)* 2018; **97**: e10831 [PMID: 29879017 DOI: 10.1097/MD.0000000000010831]

153 **Tan D**, Fu Y, Su Q, Wang H. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. *Medicine (Baltimore)* 2016; **95**: e3837 [PMID: 27310960 DOI: 10.1097/MD.0000000000003837]

154 **Gunawardene A**, Dennett E, Larsen P. Prognostic value of multiple cytokine analysis in colorectal cancer: a systematic review. *J Gastrointest Oncol* 2019; **10**: 134-143 [PMID: 30788169 DOI: 10.21037/jgo.2018.07.11]

155 **Murray PJ**. Macrophage Polarization. *Annu Rev Physiol* 2017; **79**: 541-566 [PMID: 27813830 DOI: 10.1146/annurev-physiol-022516-034339]

156 **Dang VD**, Hilgenberg E, Ries S, Shen P, Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. *Curr Opin Immunol* 2014; **28**: 77-83 [PMID: 24637161 DOI: 10.1016/j.coi.2014.02.009]

157 **Gunter MJ**, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D, Sinha R. A prospective study of serum C-reactive protein and colorectal cancer risk in men. *Cancer Res* 2006; **66**: 2483-2487 [PMID: 16489056 DOI: 10.1158/0008-5472.CAN-05-3631]

158 **Sun L**, Hu S, Yu L, Guo C, Sun L, Yang Z, Qi J, Ran Y. Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis. *Int J Cancer* 2016; **138**: 2724-2731 [PMID: 26756179 DOI: 10.1002/ijc.29993]

159 **Feng Z**, Chen JW, Feng JH, Shen F, Cai WS, Cao J, Xu B. The association between serum ferritin with colorectal cancer. *Int J Clin Exp Med* 2015; **8**: 22293-22299 [PMID: 26885206]

160 **Yan G**, Liu T, Yin L, Kang Z, Wang L. Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with colorectal cancer: a meta-analysis. *Cell Mol Biol (Noisy-le-grand)* 2018; **64**: 94-102 [PMID: 29808807]

161 **Kawamura M**, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. *Eur J Cancer* 2012; **48**: 2244-2251 [PMID: 22197219 DOI: 10.1016/j.ejca.2011.11.032]

162 **Toiyama Y**, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. *Int J Oncol* 2012; **40**: 560-566 [PMID: 22038159 DOI: 10.3892/ijo.2011.1247]

163 **Matsushita K**, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, Inoue Y, Kusunoki M. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. *Ann Surg Oncol* 2012; **19 Suppl 3**: S518-S527 [PMID: 21845497 DOI: 10.1245/s10434-011-1993-8]

164 **Werner S**, Krause F, Rolny V, Strobl M, Morgenstern D, Datz C, Chen H, Brenner H. Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting. *Clin Cancer Res* 2016; **22**: 1725-1733 [PMID: 26561557 DOI: 10.1158/1078-0432.CCR-15-1268]

165 **Väyrynen JP**, Vornanen J, Tervahartiala T, Sorsa T, Bloigu R, Salo T, Tuomisto A, Mäkinen MJ. Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. *Int J Cancer* 2012; **131**: E463-E474 [PMID: 21918979 DOI: 10.1002/ijc.26435]

166 **Wilson S**, Damery S, Stocken DD, Dowswell G, Holder R, Ward ST, Redman V, Wakelam MJ, James J, Hobbs FD, Ismail T. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. *Br J Cancer* 2012; **106**: 1431-1438 [PMID: 22433968 DOI: 10.1038/bjc.2012.93]

167 **Meng C**, Yin X, Liu J, Tang K, Tang H, Liao J. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis. *PLoS One* 2018; **13**: e0207039 [PMID: 30458003 DOI: 10.1371/journal.pone.0207039]

168 **Toiyama Y**, Tanaka K, Kitajima T, Shimura T, Kawamura M, Kawamoto A, Okugawa Y, Saigusa S, Hiro J, Inoue Y, Mohri Y, Goel A, Kusunoki M. Elevated serum angiopoietin-like protein 2 correlates with the metastatic properties of colorectal cancer: a serum biomarker for early diagnosis and recurrence. *Clin Cancer Res* 2014; **20**: 6175-6186 [PMID: 25294915 DOI: 10.1158/1078-0432.CCR-14-0007]

169 **Jiang H**, Fu XG, Chen YT. Serum level of endothelial cell-specific molecule-1 and prognosis of colorectal cancer. *Genet Mol Res* 2015; **14**: 5519-5526 [PMID: 26125749 DOI: 10.4238/2015.May.25.3]

170 **Wang TB**, Chen ZG, Wei XQ, Wei B, Dong WG. Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer. *ANZ J Surg* 2011; **81**: 694-699 [PMID: 22295309]

171 **Ferroni P**, Formica V, Della-Morte D, Lucchetti J, Spila A, D'Alessandro R, Riondino S, Guadagni F, Roselli M. Prognostic value of glycated hemoglobin in colorectal cancer. *World J Gastroenterol* 2016; **22**: 9984-9993 [PMID: 28018105 DOI: 10.3748/wjg.v22.i45.9984]

172 **Willumsen N**, Jorgensen LN, Karsdal MA. Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer. *Cancer Biol Ther* 2019; **20**: 692-699 [PMID: 30626261 DOI: 10.1080/15384047.2018.1550571]

173 **Kantola T**, Väyrynen JP, Klintrup K, Mäkelä J, Karppinen SM, Pihlajaniemi T, Autio-Harmainen H, Karttunen TJ, Mäkinen MJ, Tuomisto A. Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers. *Br J Cancer* 2014; **111**: 1605-1613 [PMID: 25137019 DOI: 10.1038/bjc.2014.456]

174 **Ben QW**, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. *Int J Oncol* 2009; **34**: 821-828 [PMID: 19212687]

175 **Toiyama Y**, Miki C, Inoue Y, Kawamoto A, Kusunoki M. Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis. *J Surg Oncol* 2009; **99**: 368-372 [PMID: 19204971 DOI: 10.1002/jso.21246]

176 **Miao X**, Zhang Y, Sun J, Cui S, Meng Q, Zhu K, Hu X, Wang T. Elevated serum DAND5 is associated with metastasis and predicts poor prognosis in colorectal cancer. *United European Gastroenterol J* 2017; **5**: 725-734 [PMID: 28815037 DOI: 10.1177/2050640616674838]

177 **Kumor A**, Daniel P, Pietruczuk M, Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. *Int J Colorectal Dis* 2009; **24**: 275-281 [PMID: 18979105 DOI: 10.1007/s00384-008-0605-y]

178 **Zeng J**, Tang ZH, Liu S, Guo SS. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. *World J Gastroenterol* 2017; **23**: 1780-1786 [PMID: 28348483 DOI: 10.3748/wjg.v23.i10.1780]

179 **Nebiker CA**, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F, Cremonesi E, Huber X, Padovan E, Angrisani B, Droeser RA, Rosso R, Bolli M, Oertli D, von Holzen U, Adamina M, Muraro MG, Mengus C, Zajac P, Sconocchia G, Zuber M, Tornillo L, Terracciano L, Spagnoli GC. GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer. *Clin Cancer Res* 2014; **20**: 3094-3106 [PMID: 24737547 DOI: 10.1158/1078-0432.CCR-13-2774]

180 **Hu H**, Sun L, Guo C, Liu Q, Zhou Z, Peng L, Pan J, Yu L, Lou J, Yang Z, Zhao P, Ran Y. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. *Clin Cancer Res* 2009; **15**: 5485-5493 [PMID: 19706805 DOI: 10.1158/1078-0432.CCR-08-2491]

181 **Oladipo O**, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell PJ, Johnston PG, Stevenson M, Kay EW, Wilson RH, Waugh DJ. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. *Br J Cancer* 2011; **104**: 480-487 [PMID: 21285972 DOI: 10.1038/sj.bjc.6606055]

182 **Jiang Z**, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. *Mol Biol Rep* 2010; **37**: 3029-3036 [PMID: 19821051 DOI: 10.1007/s11033-009-9873-z]

183 **Akishima-Fukasawa Y**, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. *Am J Clin Pathol* 2009; **132**: 202-10; quiz 307 [PMID: 19605814 DOI: 10.1309/AJCPK35VZJEWCUTL]

184 **Tuomisto A**, García-Solano J, Sirniö P, Väyrynen J, Pérez-Guillermo M, Mäkinen MJ, Conesa-Zamora P. HIF-1α expression and high microvessel density are characteristic features in serrated colorectal cancer. *Virchows Arch* 2016; **469**: 395-404 [PMID: 27421843 DOI: 10.1007/s00428-016-1988-8]

185 **Davoine F**, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. *Front Immunol* 2014; **5**: 570 [PMID: 25426119 DOI: 10.3389/fimmu.2014.00570]

186 **Amin K**. The role of mast cells in allergic inflammation. *Respir Med* 2012; **106**: 9-14 [PMID: 22112783 DOI: 10.1016/j.rmed.2011.09.007]

187 **Zhang R**, Qi F, Zhao F, Li G, Shao S, Zhang X, Yuan L, Feng Y. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. *Cell Death Dis* 2019; **10**: 273 [PMID: 30894509 DOI: 10.1038/s41419-019-1435-2]

188 **Calon A**, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, Byrom D, Riera A, Rossell D, Mangues R, Massagué J, Sancho E, Batlle E. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. *Cancer Cell* 2012; **22**: 571-584 [PMID: 23153532 DOI: 10.1016/j.ccr.2012.08.013]

189 **Li Z**, Zhou J, Zhang J, Li S, Wang H, Du J. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. *Int J Cancer* 2019 [PMID: 30873585 DOI: 10.1002/ijc.32278]

190 **Joo YE**, Seo KS, Kim J, Kim HS, Rew JS, Park CS, Kim SJ. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma. *J Korean Med Sci* 1999; **14**: 417-423 [PMID: 10485622 DOI: 10.3346/jkms.1999.14.4.417]

191 **Woo HD**, Kim K, Kim J. Association between preoperative C-reactive protein level and colorectal cancer survival: a meta-analysis. *Cancer Causes Control* 2015; **26**: 1661-1670 [PMID: 26376895 DOI: 10.1007/s10552-015-0663-8]

192 **Gupta D**, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. *Nutr J* 2010; **9**: 69 [PMID: 21176210 DOI: 10.1186/1475-2891-9-69]

193 **Ghuman S**, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W. Serum inflammatory markers and colorectal cancer risk and survival. *Br J Cancer* 2017; **116**: 1358-1365 [PMID: 28376082 DOI: 10.1038/bjc.2017.96]

194 **Lu X**, Guo W, Xu W, Zhang X, Shi Z, Zheng L, Zhao W. Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients. *Cancer Manag Res* 2018; **11**: 229-249 [PMID: 30636896 DOI: 10.2147/CMAR.S185350]

195 **Lee JH**, Choi JW, Kim YS. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis. *J Gastrointestin Liver Dis* 2011; **20**: 287-291 [PMID: 21961097]

**P-Reviewer:** Sung WW, Temraz S **S-Editor:** Ma YJ **L-Editor:**  A **E-Editor:** Ma YJ

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0



**Figure 1** **Phenotypic spectrum of macrophages.** The illustration portrays the heterogeneity of immune cell main categories in producing inflammatory mediators and growth factors based on their activation state. The image illustrates the spectrum model of macrophage polarization based on the M1-M2 paradigm. Macrophage polarization describes the type of macrophage activation at a given point in space and time[155]. The polarization can be viewed as a continuum, with M1 (pro-inflammatory) and M2 (anti-inflammatory) as the extremes. The M1 and M2 designations are based on *in vitro* stimulation with either interferon gamma (M1) or interleukin 4 (M2) without environmental influence[54]; *in vivo*, stimulation of macrophages with multiple cytokines may result in mixed phenotypes. The image shows examples of transcription factors, cell surface molecules and inflammatory mediators commonly associated with M1 and M2 polarization states. Similarly to macrophages, different activation states have been associated with other immune cell types such as neutrophils[57,58], B cells[56], and plasma cells[156]. CCL: C-C motif chemokine ligand; CD80: CD80 molecule; CD86: CD86 molecule; CXCL: C-X-C motif chemokine ligand; GATA3: GATA binding protein 3; IL: Interleukin; IRF: Interferon regulatory factor; MHC II: Major histocompatibility complex, type II; MMP1: Matrix metallopeptidase 1; MRC1; Mannose receptor C-type 1; pSTAT1: Phosphorylated signal transducer and activator of transcription 1; STAB1: Stabilin 1; TGFB1: Transforming growth factor beta 1; TNF: Tumor necrosis factor; VEGFA: Vascular endothelial growth factor A.



**Figure 2 Overview of the effects of systemic inflammation in colorectal cancer.** The illustration portrays some of the molecules and phenomena considered important in the pathogenesis of colorectal cancer associated systemic inflammation. Some markers showing increased circulating concentrations in colorectal cancer patients are listed in the center. ALB: Albumin; CCL: C-C motif chemokine ligand; CXCL: C-X-C motif chemokine ligand; CRP: C-reactive protein; CSF: Colony stimulating factor; FGF2: Fibroblast growth factor 2; Gln: Glutamine; HP: Haptoglobin; IL: Interleukin; MMP: Matrix metallopeptidase; OPN: Osteopontin; PDGF: Platelet derived growth factor; SAA1: Serum amyloid A1; THPO: Thrombopoietin; TIMP1: TIMP metallopeptidase inhibitor 1; VEGFA: Vascular endothelial growth factor A; VEGFC: Vascular endothelial growth factor C; vWF: von Willebrand factor



**Figure 3 Overview of the potential pathways involved in the suppression of anti-tumor immunity by myeloid derived suppressor cells.** ARG1: Arginase 1; IDO1: Indoleamine 2,3-dioxygenase 1; IL10: Interleukin 10; MDSCs: Myeloid derived suppressor cells; PD1: Programmed cell death protein 1; PDL1: Programmed death ligand 1; TGFB1: Transforming growth factor beta 1.

**Table 1 Some systemic inflammatory markers showing altered circulating levels in colorectal cancer patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Marker** |  | **Function** | **Detection method** | **Samples** | **Ref.** |
| **Acute phase proteins** |  |  |  |  |  |
| CRP (C-reactive protein) | ↑ | Acute phase protein | ELISA | serum | Gunter *et al*[157] |
| HP (haptoglobin) | ↑ | Hemoglobin-binding acute phase protein | ELISA | serum | Sun *et al*[158] |
| Ferritin | ↓ | Protein that stores iron | meta-analysis | serum | Feng *et al*[159] |
| **Cytokines and chemokines** |  |  |  |  |  |
| IL6 | ↑ | Proinflammatory cytokine | meta-analysis | serum | Xu *et al*[23] |
| IL7 | ↑ | Cytokine involved in lymphocyte maturation | Multiplex magnetic bead assay | serum | Kantola *et al*[18] |
| IL17A | ↑ | Proinflammatory cytokine | meta-analysis | serum | Yan *et al*[160] |
| IL22 | ↑ | Cytokine contributing to tissue homeostasis | meta-analysis | serum | Yan *et al*[160] |
| IL23 | ↑ | Proinflammatory cytokine | meta-analysis | serum | Yan *et al*[160] |
| CCL2 | ↓ | Recruitment of monocytes and macrophages | Multiplex magnetic bead assay | serum | Kantola *et al*[18] |
| CXCL5 | ↑ | Recruitment of neutrophils | ELISA | serum | Kawamura *et al*[161] |
| CXCL8 (IL8) | ↑ | Recruitment of neutrophils | meta-analysis | serum | Jin *et al*[24] |
| CXCL10 | ↑ | Recruitment of T cells and NK cells | ELISA | serum | Toiyama et el [162] |
| CXCL16 | ↑ | Recruitment of T cells and NK cells | ELISA | serum | Matsushita *et al*[163] |
| SPP1 (secreted phosphoprotein 1) | ↑ | Leukocyte chemotaxis | streptavidin–biotin sandwich assay | serum | Werner *et al*[164] |
| **Protease enzymes and their inhibitors** |  |  |  |  |  |
| MMP8 | ↑ | Protease enzyme also cleaving cytokines | immunofluorometric assay | serum | Väyrynen *et al*[165] |
| MMP9 |  | Degradation of extracellular matrix and regulation of neutrophil action | ELISA | serum | Wilson *et al*[166] |
| TIMP1 | ↑ | Inhibitor of metalloproteinases | meta-analysis | serum | Meng *et al*[167] |
| **Growth factors and their inhibitors** |  |  |  |  |  |
| ANGPTL2 | ↑ | Growth factor contributing to the regulation of inflammation and angiogenesis | ELISA | serum | Toiyama *et al*[168] |
| ESM1 | ↑ | Secreted angiogenic factor | ELISA | serum | Jiang *et al*[169] |
| PDGFB | ↑ | Proliferation of mesenchymal cells | Multiplex magnetic bead assay | serum | Kantola *et al*[18] |
| VEGFA | ↑ | Vascular growth factor |  |  |  |
| VEGFC | ↑ | Vascular growth factor | ELISA | serum | Wang *et al*[170] |
| **Markers of metabolism** |  |  |  |  |  |
| glucose (fasting) | ↑ | Energy source | G6PD | serum | Ferroni *et al*[171] |
| HbA1c |  | Oxygen carrier | HPLC Analyzer | serum | Ferroni *et al*[171] |
| insulin (fasting) | ↑ | Regulator of metabolism | ELISA | serum | Ferroni *et al*[171] |
| **ECM/endothelium-derived signaling proteins** |  |  |  | [172] |  |
| Endostatin | ↑ | Angiogenesis inhibitor | ELISA | serum | Kantola *et al*[173] |
| POSTN (periostin) | ↑ | ECM protein | ELISA | serum | Ben *et al*[174] |
| VASTATIN | ↑ | Collagen VIII derived matrikine | ELISA | serum | Willumsen et al[172] |
| VCAM-1 (soluble) | ↑ | Multifunctional | ELISA | serum | Toiyama et el[175] |
| **Other signaling molecules** |  |  |  |  |  |
| DAND5 | ↑ | BMP inhibitor | ELISA | serum | Miao *et al*[176] |
| LRP (leptin) | ↓ | Regulator of metabolism | ELISA | serum | Kumor *et al*[177] |
| Resistin | ↑ | Regulator of metabolism | ELISA | serum | Kumor *et al*[177] |
|  |  |  |  |  |  |

ECM: Extracellular matrix; G6PD: Hexokinase/glucose-6-phosphate dehydrogenase.

**Table 2** **Examples of inflammatory mediators reported to be expressed by colorectal cancer cells**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Inflammatory mediator** | **Function** | **Detection method** | **Samples** | **Ref.** |
| IL6 | Proinflammatory cytokine | IHC, RT-PCR | FFPE CRC specimens | Zeng *et al*[178] |
| CSF1 | Proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells; polarization of pro-tumor M2 macrophages | IHC | FFPE CRC specimens | Nebiker *et al*[179] |
| CSF2 | Proliferation, differentiation, and survival of monocytes, macrophages, granulocytes and bone marrow progenitor cells, polarization of anti-tumor M1 macrophages | IHC | FFPE CRC specimens | Nebiker *et al*[179] |
| CCL2 | Recruitment of monocytes and macrophages | IHC, WB | CRC cell lines, FFPE CRC specimens | Hu *et al*[180] |
| CXCL1 | Recruitment of neutrophils | IHC | FFPE CRC specimens | Oladipo *et al*[181] |
| CXCL8 | Recruitment of neutrophils | IHC, IF, WB | CRC cell lines, FFPE CRC specimens | Xiao *et al*[30] |
| CXCL8 | Recruitment of neutrophils | IHC | FFPE CRC specimens | Oladipo *et al*[181] |
| CXCL10 | Recruitment of T cells and NK cells | IHC, RT-PCR | CRC cell lines, FFPE CRC specimens | Jiang *et al*[182] |
| CXCL12 | Recruitment of lymphocytes and endothelial progenitor cells | IHC | FFPE CRC specimens | Akishima-Fukasawa *et al*[183] |
| VEGFA | Angiogenesis | IHC | FFPE CRC specimens | Tuomisto *et al*[184] |

CRC: Colorectal cancer; FFPE: Formalin-fixed paraffin-embedded; IHC: Immunohistochemistry; IF: Immunofluorescence; RT-PCR: Real-time polymerase chain reaction; WB: Western blot.

**Table 3** **Examples of inflammatory mediators produced by different inflammatory cells**

|  |  |  |  |
| --- | --- | --- | --- |
| **Cell type** | **Inflammatory mediators** | **Functions** | **Ref.** |
| M1 macrophage | IL6, TNF, IL12A, IL12B, IL23A, CXCL5, CXCL9, CXCL10, CXCL11, | Activation of inflammation | Murray *et al*[178] |
| M2 macrophage | IL10, CCL4, CCL13, CCL17, CCL18, MMP1, TGFB1 | Resolution of inflammation | Murray *et al*[47] |
| Th1 lymphocyte | IFNG, IL2 | Activation of cytotoxic immune response | Zhu *et al*[55] |
| Th2 lymphocyte | IL4, IL5, IL10, IL13 | Activation of humoral immune response | Zhu *et al*[55] |
| Th17 lymphocyte | IL17A, IL17F, IL21, IL22 | Activation of neutrophils | Zhu *et al*[55] |
| Treg lymphocyte | TGFB | Immunosuppression | Zhu *et al*[55] |
| Plasma cell | IL10, IL35. TNF, IL17A, CSF2 | Both pro- and anti-inflammatory mediators | Dang *et al*[156] |
| Neutrophil | IL1A, IL1B, IL1RA, IL6, IL12 CXCL8, CXCL9, CXCL10, CXCL11, CCL2, CCL3, CCL4, TGFB1, VEGFA | Activation of inflammation; depending on the type of polarization, also anti-inflammatory mediators are secreted | Tecchio *et al*[58] |
| Eosinophil | IL1A, IL2, IL4, IL6, IL12, CXCL1, CXCL8, CXCL10, CCL3, CCL5, CCL11 | Th2 type immune responses | Davoine *et al*[185] |
| Myeloid derived suppressor cell | IL10, TGFB | Immunosuppression | Bronte *et al*[87] |
| Mast cell | IL4, IL5, IL6, TNF, CSF2 | Th2 type immune responses | Amin *et al*[186] |

**Table 4** **Examples of inflammatory mediators reported to be expressed by colorectal cancer associated fibroblasts**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Inflammatory mediator** | **Function** | **Detection method** | **Samples** | **Ref.** |
| IL6 | Proinflammatory cytokine | IF | FFPE CRC specimens | Nagasaki *et al*[29] |
| IL6 | Proinflammatory cytokine | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| IL6 | Proinflammatory cytokine | ELISA | CAFs isolated from human CRC tissue | Zhang *et al*[187] |
| IL8 | Proinflammatory cytokine | ELISA | CAFs isolated from human CRC tissue | Zhang *et al*[187] |
| IL11 | Anti-inflammatory cytokine | qRT-PCR | CAFs isolated from human CRC tissue | Calon *et al*[188] |
| TGFB | Immunosuppression, inhibition of cytotoxic T cells and Th1 cells | IHC, WB | Cell culture (CRC cells, fibroblasts) | Hawingkels *et al*[68] |
| CXCL5 | Recruitment of neutrophils | IHC, In situ hybridization | FFPE CRC specimens | Li *et al*[189] |
| CXCL8 | Recruitment of neutrophils | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| CCL5 | Recruitment of T cells | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| MMP1 | ECM degradation | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| MMP2 | ECM degradation | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| MMP3 | ECM degradation | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| MMP9 | ECM degradation | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| TIMP1 | Inhibition of MMPs | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| TIMP1 | Inhibition of MMPs | IHC, in situ hybridization | FFPE CRC specimens | Joo *et al*[190] |
| TIMP2 | Inhibition of MMPs | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |
| TIMP2 | Inhibition of MMPs | IHC, in situ hybridization | FFPE CRC specimens | Joo *et al*[190] |
| VEGFA | Angiogenesis | LC-MS/MS | Cell culture (human cancer associated fibroblasts) | De Boeck *et al*[63] |

CRC: Colorectal cancer; ECM: Extracellular matrix; FFPE: Formalin fixed paraffin embedded; IHC: Immunohistochemistry; IF: Immunofluorescence; LC-MS/MS: Liquid chromatography with tandem mass spectrometry; MMP: Matrix metalloproteinase; RT-PCR: Real-time polymerase chain reaction; WB: Western blot.

**Table 5** **Selected systemic inflammation based prognostic markers in colorectal cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Marker** | **Ref.** | **Study design** | **Study population** | **Outcome, HR** |
| **Acute phase proteins** |  |  |  |  |
| CRP | Woo *et al*[191] | Meta-analysis, 21 studies | 3934 CRC patients, stage I-II | OS, HR 2.04 (1.45–2.86); CSS, HR 4.37 (2.63–7.27); DFS, HR 1.88 (0.97–3.67) |
| Albumin | Gupta *et al*[192] | Systematic review, 12 studies | 3644 CRC patients, stage I-IV | Low albumin associated with worse survival (no meta-analysis conducted) |
| Albumin | Ghuman *et al*[193] | Case-case study within a prospective cohort study (AMORIS) | 4764 CRC patients, stage I-IV | OS, HR 0.57 (0.29–1.14); CSS, HR 0.36 (0.16–0.85) |
| mGPS | Lu *et al*[194] | Meta-analysis, 41 studies | 9839 CRC patients, stage I-IV | OS, HR 2.20 (1.88–2.57); CSS, HR 1.86 (1.59–2.17) |
| HP (haptoglobin) | Ghuman *et al*[193] | Case-case study within a prospective cohort study (AMORIS) | 4764 CRC patients, stage I-IV | OS, HR 1.28 (1.08–1.51); CSS, HR 1.17 (0.95–1.45) |
| **Blood cell count parameters** |  |  |  |  |
| Neutrophil-to-lymphocyte ratio | Li *et al*[148] | Meta-analysis, 16 studies | 5897 CRC patients, stage I-IV | OS, HR 1.66 (1.36–2.02); CSS, HR 2.27 (1.75–2.96); DFS, HR 1.54, (1.18–2.02) |
| Lymphocyte-to-monocyte ratio | Tan *et al*[149] | Meta-analysis, 15 studies | 11783 CRC patients, stage I-IV | OS, HR 0.57 (0.52-0.62); CSS, HR 0.55 (0.32-0.95); DFS, HR 0.77 (0.70-0.84) |
| Platelet count | Rao *et al*[152] | Meta-analysis, 9 studies | 3413 CRC patients, stage I-IV | OS, HR 2.11 (1.68-2.65); DFS, HR 2.51 (1.84-3.43) |
| Platelet-to-lymphocyte ratio | Tan *et al*[153] | Meta-analysis, 15 studies | 3991 CRC patients, stage I-IV | OS, HR 1.53 (1.24–1.89), DFS, HR 1.68 (1.07–2.62) |
| Anemia | Wilson *et al*[150] | Meta-analysis, 12 studies | 3588 CRC patients, stage I-IV | OS, HR 1.56 (1.30-1.88), DFS, HR 1.34 (1.11-1.61) |
| **Cytokines, chemokines, and their receptors** |  |  |  |  |
| IL6 | Xu *et al*[23] | Meta-analysis, 10 studies | 860 CRC patients, stage I-IV | OS, HR 1.76 (1.42–2.19); DFS, HR 2.97 (1.76–5.01) |
| TNFRSF11B (Osteoprotegerin) | Birgisson *et al*[20] | Prospective cohort study | 261 stage II-IV CRC patients | OS, HR 3.33 |
| **Protease enzymes and their inhibitors** |  |  |  |  |
| TIMP1 | Lee *et al*[195] | Meta-analysis, 10 studies | 1477 CRC patients, stage I-IV | OS, HR 2.25 (1.56-3.25) |

CRC: Colorectal cancer; CSS: Cancer-specific survival; DFS: Disease-free survival; HR: Hazard ratio; OS: Overall survival.